Vanda Pharmaceuticals Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
VNDA Nasdaq 2836 www.vandapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vanda Pharmaceuticals Inc.

US High Growth Tech Stocks With Strong Potential - Feb 28th, 2025 5:09 pm
February 2025 Penny Stocks To Keep An Eye On - Feb 27th, 2025 11:05 am
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" - Feb 24th, 2025 12:00 pm
Q4 2024 Vanda Pharmaceuticals Inc Earnings Call - Feb 14th, 2025 2:41 pm
Vanda Pharmaceuticals Inc (VNDA) Q4 2024 Earnings Call Highlights: Revenue Growth Amidst Challenges - Feb 14th, 2025 7:20 am
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates - Feb 13th, 2025 10:15 pm
Vanda: Q4 Earnings Snapshot - Feb 13th, 2025 9:18 pm
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - Feb 13th, 2025 9:01 pm
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 - Feb 5th, 2025 9:30 pm
Vanda and AnaptysBio link for generalised pustular psoriasis therapy - Feb 4th, 2025 11:37 am
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist - Feb 3rd, 2025 12:30 pm
BioAge drops obesity drug; Akero, 89bio cash in on MASH data - Jan 29th, 2025 10:39 am
US Exchange Penny Stocks To Watch In January 2025 - Jan 28th, 2025 1:06 pm
Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis - Jan 27th, 2025 12:00 pm
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate - Jan 16th, 2025 6:47 pm
Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review - Jan 8th, 2025 9:17 pm
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now? - Jan 6th, 2025 4:54 pm
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates - Jan 6th, 2025 1:59 pm
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Dec 24th, 2024 12:47 pm
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera - Dec 20th, 2024 2:13 pm